The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity
Open accessAbstract
Background—: Cardiotoxicity is a leading cause for drug attrition during pharmaceutical development and has resulted in numerous preventable patient deaths. Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population. Here we generated a library of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) from patients with various hereditary cardiac disorders to model differences in cardiac drug toxicity susceptibility for patients of different genetic backgrounds. Methods and Results—: Action potential duration and drug-induced arrhythmia were measured at the single cell level in hiPSC-CMs derived from healthy subjects and patients with hereditary long QT syndrome, familial hypertrophic cardiomyopathy, and familial dilated cardiomyopathy. Disease phenotypes were verified in long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy hiPSC-CMs by immunostaining and single cell patch clamp. Human embryonic stem cell–derived cardiomyocytes (hESC-CMs) and the human ether-a-go-go –related gene expressing human embryonic kidney cells were used as controls. Single cell PCR confirmed expression of all cardiac ion channels in patient-specific hiPSC-CMs as well as hESC-CMs, but not in human embryonic kidney cells. Disease-specific hiPSC-CMs demonstrated increased susceptibility to known cardiotoxic drugs as measured by action potential duration and quantification of drug-induced arrhythmias such as early afterdepolarizations and delayed afterdepolarizations. Conclusions—: We have recapitulated drug-induced cardiotoxicity profiles for healthy subjects, long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy patients at the single cell level for the first time. Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go –related gene test or healthy control hiPSC-CM/hESC-CM screening assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 1×
“Differentiation of Patient-Specific hiPSCs Into Cardiomyocytes Patient-specific hiPSCs were differentiated into cardiomyocytes using standard 3D EB differentiation protocols as previously described.(28) Differentiated EBs exhibited spontaneously contracting foci as early as ten days following initiation of cardiac dif…”
MethodPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Classen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Keating, M. T., & Sanguinetti, M. C. (2001) · Cell · doi:10.1016/s0092-8674(01)00243-4 · Cited by 1,001
A nonviral minicircle vector for deriving human iPS cells
Jia, F., Wilson, K. D., Sun, N., Gupta, D. M., Huang, M., Li, Z., Panetta, N. J., Chen, Z. Y., Robbins, R. C., Kay, M. A., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1426 · Cited by 734 · cited 1×
“hESC and hiPSC lines were differentiated via embryoid body (EB) formation using a previously described protocol.(27) Briefly, on day 0 of differentiation, hESC and hiPSC colonies were dissociated with Accutase (Sigma) into small clumps of 10 to 20 cells.”
MethodSelf-citationPatient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696
Self-citationPatient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690
Cited by
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Lewis-Israeli, Y. R., Wasserman, A. H., Gabalski, M. A., Volmert, B. D., Ming, Y., Ball, K. A., Yang, W., Zou, J., Ni, G., Pajares, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25329-5 · Cited by 536
Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications
Mathur, A., Loskill, P., Shao, K., Huebsch, N., Hong, S., Marcus, S. G., Marks, N., Mandegar, M., Conklin, B. R., Lee, L. P., et al. (2015) · Scientific Reports · doi:10.1038/srep08883 · Cited by 519
Karakikes, I., Ameen, M., Termglinchan, V., & Wu, J. C. (2015) · Circulation Research · doi:10.1161/circresaha.117.305365 · Cited by 478
Self-citationHuman cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity
Richards, D. J., Li, Y., Kerr, C. M., Yao, J., Beeson, G. C., Coyle, R. C., Chen, X., Jia, J., Damon, B., Wilson, R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0539-4 · Cited by 439
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404
Self-citationInduced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Passini, E., Britton, O. J., Lu, H. R., Rohrbacher, J., Hermans, A. N., Gallacher, D. J., Greig, R. J. H., Bueno-Orovio, A., & Rodriguez, B. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00668 · Cited by 326
Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000570 · Cited by 302
Self-citationTranslation of Human-Induced Pluripotent Stem Cells
Sayed, N., Liu, C., & Wu, J. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.083 · Cited by 279
Self-citationInduced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications
Yoshida, Y., & Yamanaka, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.311080 · Cited by 264
Current status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
Goldfracht, I., Efraim, Y., Shinnawi, R., Kovalev, E., Huber, I., Gepstein, A., Arbel, G., Shaheen, N., Tiburcy, M., Zimmermann, W. H., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.016 · Cited by 222
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Self-citationWu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., Lan, F., Churko, J. M., Sallam, K. I., Matsa, E., Sharma, A., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.04.020 · Cited by 177
“Human iPSC-CMs are utilized for cardiovascular disease modeling and drug screening (Itzhaki et al., 2011; Lan et al., 2013; Liang et al., 2013; Sun et al., 2012).”
BackgroundMethodSelf-citationInspiration from heart development: Biomimetic development of functional human cardiac organoids
Richards, D. J., Coyle, R. C., Tan, Y., Jia, J., Wong, K., Toomer, K., Menick, D. R., & Mei, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.021 · Cited by 166
Tzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
Self-citationProgress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Self-citationMatsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
Self-citationModeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures
Sacchetto, C., Vitiello, L., de Windt, L. J., Rampazzo, A., & Calore, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093404 · Cited by 91
Kerscher, P., Turnbull, I. C., Hodge, A. J., Kim, J., Seliktar, D., Easley, C. J., Costa, K. D., & Lipke, E. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.011 · Cited by 88
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes
Giacomelli, E., Mummery, C. L., & Bellin, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2546-5 · Cited by 60
Lam, C. K., Tian, L., Belbachir, N., Wnorowski, A., Shrestha, R., Ma, N., Kitani, T., Rhee, J.-W., & Wu, J. C. (2019) · Circulation Research · doi:10.1161/circresaha.118.314202 · Cited by 39
Self-citationHuman iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Drug-induced long-QT syndrome and torsade de pointes: an underrated problem?
Rao, P., & Kowey, P. R. (2014) · Europace · doi:10.1093/europace/eut331 · Cited by 4
Metadata
- Authors
- Liang, P., Lan, F., Lee, A. S., Gong, T., Sanchez-Freire, V., Wang, Y., Diecke, S., Sallam, K., Knowles, J. W., Wang, P. J., Nguyen, P. K., Bers, D. M., Robbins, R. C., & Wu, J. C.
- Venue
- Circulation
- Published
- 2013-04-23
- Volume
- 127
- Issue
- 16
- Pages
- 1677-1691
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1975396117
- Cited by
- 537
- References
- 58
- FWCI
- 41.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.